US Stock MarketDetailed Quotes
MNMD Mind Medicine
- 7.1600
- +0.1400+1.99%
Close Dec 13 16:00 ET
- 7.1500
- -0.0100-0.14%
Post 20:01 ET
525.05MMarket Cap-4.19P/E (TTM)
7.2900High6.9000Low1.19MVolume7.0200Open7.0200Pre Close8.38MTurnover2.22%Turnover RatioLossP/E (Static)73.33MShares12.220052wk High2.00P/B382.59MFloat Cap3.270052wk Low--Dividend TTM53.43MShs Float86.5500Historical High--Div YieldTTM5.56%Amplitude2.1200Historical Low7.0620Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Mind Medicine Stock Forum
MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)
Mind Medicine (MindMed) (NASDAQ: MNMD), a clinical-stage biopharmaceutical company, announced that its MM120 Orally Disintegrating Tablet (ODT) has been granted an Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (...
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
$Mind Medicine (MNMD.US)$
$36 target!!!!!
https://www.moomoo.com/news/post/41181597/roth-mkm-initiates-mind-medicine-mnmdus-with-buy-rating-announces?futusource=news_stock_stockpagenews&ns_stock_id=37125992&report_id=37125992&report_type=stock&src=2&main_broker=WzEwMDdd&client_hour_clock=24&us_cid=73925127&channel=4&skintype=3&level=2&global_content={%22promote_content%22:%22mm:post:41181597%22,%22invite%22:73925127}&data_ticket=1721821266767476
$36 target!?!?
https://www.moomoo.com/news/post/41181597?futusource=news_stock_stockpagenews&ns_stock_id=37125992&report_id=37125992&report_type=stock&src=2&main_broker=WzEwMDdd&client_hour_clock=24&us_cid=73925127&channel=4&skintype=3&level=1&global_content=%7B%22promote_content%22%3A%22mm%3Apost%3A41181597%22%2C%22invite%22%3A73925127%7D&data_ticket=d852726825d53ffa91432d8eef415178
A small position however, it isn't showing up on the ticker at all!
https://www.fda.gov/news-events/press-announcements/fda-issues-first-draft-guidance-clinical-trials-psychedelic-drugs
No comment yet